GSK reported Cabenuva trial success. GSK stock trades 1.38 percent below its prior close.

Published on 10/08/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cabenuva met its primary endpoint in CROWN on October 6, 2026. GSK stock stood at EUR 20.70 versus EUR 20.99, down 1.38 percent.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK was trading at EUR 20.70 at Lang & Schwarz on October 8, 2026 at 12:30 p.m. CEST, down 1.38 percent versus the prior close of EUR 20.99. GSK had reported on October 6, 2026 that ViiV Healthcare's Cabenuva met the primary endpoint in the phase IIIb CROWN study, according to Yahoo Finance. The result gives GSK's HIV business a fresh clinical data point, although the tested use remains investigational.

CROWN enrolled 326 participants

Cabenuva, a long-acting combination of cabotegravir and rilpivirine, achieved superior viral suppression after six months compared with standard daily oral therapy in adults and adolescents with detectable HIV-1 virus at study entry. The CROWN study enrolled approximately 326 participants across eight countries and 85 study sites, with injections administered six times a year, Yahoo Finance reported on October 6, 2026.

The qualification matters for valuation. Cabenuva is already approved for patients who are virologically suppressed on stable therapy, while the CROWN population entered treatment with detectable virus. GSK said the data would be shared with health authorities for regulatory review, and full results are planned for a scientific meeting, according to Yahoo Finance.

Q2 revenue reached GBP 8.41 billion

GSK's second-quarter 2026 revenue rose 5.30 percent year over year to GBP 8.41 billion, while net income fell 70.00 percent to GBP 435.0 million. Revenue exceeded analyst estimates by 1.00 percent, but earnings per share missed estimates by 74.00 percent, according to Simply Wall St.

Eight analysts set a Hold consensus

MarketBeat reported that eight analysts had a Hold consensus, with two Buy ratings, five Hold ratings and one Sell rating over the twelve months through October 7, 2026. The average target was GBp 2,064.38, compared with a high of GBp 2,500.00 and a low of GBp 1,500.00.

GSK reports again on October 28

GSK's London listing had a 52-week range of GBp 1,592.00 to GBp 2,282.00 and a market capitalization of GBP 71.1 billion on October 7, 2026. Investing.com listed October 28, 2026 as the next earnings date.

GSK was trading at EUR 20.70 at Lang & Schwarz on October 8, 2026 at 12:30 p.m. CEST, down 1.38 percent versus the Lang & Schwarz prior close of EUR 20.99 on October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of GSK stock.